Matt Gamber’s Biotech Newsletter

Hello all, It’s been a long time since I sent you something! I am posting the thread below on Twitter about ProQR's (PRQR) Sepofarsen ahead of Phase 3 readout in LCA10. If the formatting looks a bit strange it’s because it was originally 20 tweets strung together — I don’t…
Share
NewTop
Happy New Year! It has been over two months since I have sent out an e-mail to you all so I wanted to do an update with some new ideas I posted about to…
Share
Introduction to Short Bowel Syndrome I’m keeping the intro section short because I really want to get into the vurolenatide Phase 2 trial design and…
Share
Hi everyone! I thought I would write a quicker read today but still hopefully providing lots of value. I realize some subscribe here but don’t follow me…
Share
Introduction to Kv7 Channel Blockers Ezogabine (brand name Potiga) was approved in 2011 as the first anti-seizure medicine utilizing the Kv7 channel…
Share
Before I begin, I wanted to inform you all about an exciting development. I have started leading one call per week with a subject matter expert over at…
Share
Opiant Pharmaceuticals (NASDAQ: OPNT, $126 million market capitalization accounting for all outstanding stock options and warrants) is a micro cap…
Share
Welcome back to Part 2 of my Equillium Deep Dive. You can find Part 1, covering aGVHD, here. Today we will focus on the other indications for…
Share
See all

Matt Gamber’s Biotech Newsletter

AboutArchiveAuthors
© 2022 Matt
Privacy ∙ Terms ∙ Collection notice
Publish on Substack Get the app
Substack is the home for great writing